TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22773179

Group type: EXPERIMENTAL
Intervention: Aspheric profile (Aberration Smart Ablation [ASA])
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-aspheric profile (Tissue Saving Ablation [TSA])
Number of subjects: 30
Study: 20398378

Group type: EXPERIMENTAL
Intervention: Pre-operative fluid therapy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Routine intensive care
Number of subjects: 204

Group type: COMPARATOR
Intervention: High dependency care
Number of subjects: 204
Study: 18552616

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with MMC and single-layer AMT
Number of subjects: 37

Group type: COMPARATOR
Intervention: Trabeculectomy with MMC alone
Number of subjects: 37
Study: 16003036

Group type: EXPERIMENTAL
Intervention: Eccentric training (squats on a 25 degrees decline board, 3 x 15 repetitions twice daily for 12 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (trained as usual)
Number of subjects: 29
Study: 12766127

Group type: EXPERIMENTAL
Intervention: Reduction in ulcer area greater than the 4-week median
Number of subjects: 203

Group type: COMPARATOR
Intervention: Reduction in ulcer area less than the 4-week median
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Healers (absolute change in ulcer area at 4 weeks)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Nonhealers (absolute change in ulcer area at 4 weeks)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Healed patients (percent change in wound area at 4 weeks)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Failed to heal patients (percent change in wound area at 4 weeks)
Number of subjects: 203
Study: 10575499

Group type: EXPERIMENTAL
Intervention: PAA (Preanaesthetic Assessment) followed by PAV (Preanaesthetic Visit)
Number of subjects: 296

Group type: COMPARATOR
Intervention: PAV (without previous PAA)
Number of subjects: 296
Study: 8909736

Group type: EXPERIMENTAL
Intervention: diclofenac sodium 100 mg (preoperative administration)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: diclofenac sodium 100 mg (postoperative administration)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: diclofenac sodium 100 mg (both pre- and postoperative)
Number of subjects: 21
Study: 1869646

Group type: EXPERIMENTAL
Intervention: Topical masoprocol applied twice a day for 14 to 28 days
Number of subjects: 113

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Topical masoprocol
Number of subjects: 113
Study: 6213376

Group type: EXPERIMENTAL
Intervention: 20 mg MPA with 250 mg testosterone enanthate (TE) monthly injection
Number of subjects: 25
Study: 31608551

Group type: EXPERIMENTAL
Intervention: 300 mg pregabalin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 16
Study: 31264912

Group type: EXPERIMENTAL
Intervention: HPV vaccination (at least one dose)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: HPV vaccination after age 18
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: HPV vaccination after first vaginal intercourse
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: College education
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: HPV 16/18 positivity
Number of subjects: 375
Study: 29473223

Group type: EXPERIMENTAL
Intervention: Subcrestal placement of implants
Number of subjects: 48

Group type: COMPARATOR
Intervention: Epicrestal placement of implants
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 27447245

Group type: EXPERIMENTAL
Intervention: Deep transcranial magnetic stimulation (TMS) with H-1 coil, 120% target stimulation intensity, 18 Hz, 55 trains of 2-second duration, total 1980 pulses.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1
Study: 24585164

Group type: EXPERIMENTAL
Intervention: Nonwaste needleless setup
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nonwaste syringe setup
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard setup (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Needleless group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Syringe group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Arterial catheter samples
Number of subjects: 90
Study: 23044236

Group type: EXPERIMENTAL
Intervention: 0.5 mg/day ETV (group A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 0.5 mg/day ETV maleate (group B)
Number of subjects: 57
Study: 19562395

Group type: EXPERIMENTAL
Intervention: First causal relation categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second causal relation categories
Number of subjects: 0
Study: 18556248

Group type: EXPERIMENTAL
Intervention: Galantamine (n=13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 28
Study: 15983801

Group type: EXPERIMENTAL
Intervention: 50 ng/ml ketamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 ng/ml ketamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine (50 ng/ml or 100 ng/ml)
Number of subjects: 12
Study: 11916440

Group type: EXPERIMENTAL
Intervention: Warm retrograde continuous blood cardioplegia (RCBC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cold retrograde continuous blood cardioplegia (RCBC)
Number of subjects: 22
Study: 10606501

Group type: EXPERIMENTAL
Intervention: BrAC = 0.05%
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: BrAC = 0.1%
Number of subjects: 11

Group type: COMPARATOR
Intervention: BrAC = 0.0% (no-alcohol placebo)
Number of subjects: 11
Study: 9384642

Group type: EXPERIMENTAL
Intervention: Neutron therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 1678941

Group type: COMPARATOR
Intervention: Repetitive injections of vecuronium (Group 1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Adaptive closed-loop feedback system (Group 2)
Number of subjects: 22
Study: 6343664

Group type: EXPERIMENTAL
Intervention: Cefotetan (CTT) 2g daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cefmetazole (CMZ) 4g daily
Number of subjects: 150
Study: 29962090

Group type: EXPERIMENTAL
Intervention: Web-based acceptance and commitment therapy (ACT) program (YOLO), 4 weeks
Number of subjects: 130
Study: 27255908

Group type: EXPERIMENTAL
Intervention: Robot assisted gait training (RAGT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional physical therapy program conducted over-ground (fPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAGT and fPT combined
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance therapy only
Number of subjects: 0
Study: 25421843

Group type: EXPERIMENTAL
Intervention: Training courses on breastfeeding during pregnancy (Group A)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No training courses on breastfeeding (Group B)
Number of subjects: 77
Study: 22118823

Group type: EXPERIMENTAL
Intervention: Postprocedure IVUS minimum lumen area
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Postprocedure IVUS minimum stent area
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Postprocedure IVUS reference average lumen area
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Minimum stent area as a predictor of angiographic restenosis
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus prevalence
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Bare-metal stent use prevalence
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Attenuated plaque behind the stent struts
Number of subjects: 318
Study: 20438662

Group type: EXPERIMENTAL
Intervention: Expert Example
Number of subjects: 134

Group type: COMPARATOR
Intervention: Advanced Student Example
Number of subjects: 134
Study: 17660490

Group type: EXPERIMENTAL
Intervention: Synchronous VTE
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: VTE during chemotherapy
Number of subjects: 227
Study: 16278629

Group type: EXPERIMENTAL
Intervention: Sequential combined spinal-epidural (CSE) anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 100
Study: 11861034

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with conjugated estrogens 0.625 mg/day for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thrombin-stimulated platelets (0.1 U/ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thrombin-stimulated platelets (0.3 U/ml)
Number of subjects: 18
Study: 10455479

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg once daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Bendrofluazide (2.5 mg once daily)
Number of subjects: 81
Study: 8719258

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CREAT)
Number of subjects: 6
Study: 2611092

Group type: EXPERIMENTAL
Intervention: Intranasal lignocaine (100 mg dose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous lignocaine (100 mg dose)
Number of subjects: 6
Study: 937882

Group type: EXPERIMENTAL
Intervention: Early ambulation (during the initial 3 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Complete bed rest (for 5 days)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Early ambulation (with heart failure)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Complete bed rest (with heart failure)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Venography
Number of subjects: 29
Study: 31245885

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylactic group (2 g of cefotiam during endoscopic injection)
Number of subjects: 107

Group type: COMPARATOR
Intervention: On-demand group (no prophylactic antibiotics)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylactic group
Number of subjects: 107

Group type: COMPARATOR
Intervention: On-demand group
Number of subjects: 107
Study: 26314289

Group type: EXPERIMENTAL
Intervention: Face-to-face treatment
Number of subjects: 147

Group type: COMPARATOR
Intervention: Telephone-based treatment
Number of subjects: 147
Study: 23996977

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5016

Group type: COMPARATOR
Intervention: Minimal lifestyle intervention
Number of subjects: 5016

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 5016

Group type: EXPERIMENTAL
Intervention: Higher depression score
Number of subjects: 5016

Group type: EXPERIMENTAL
Intervention: Non-married status
Number of subjects: 5016

Group type: EXPERIMENTAL
Intervention: Never self-weighing prior to enrollment
Number of subjects: 5016
Study: 23883531

Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ProVisc
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DisCoVisc
Number of subjects: 45
Study: 20458822

Group type: EXPERIMENTAL
Intervention: Additional left atrial (LA) septal line ablation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pulmonary vein (PV) isolation with roof line, mitral isthmus line and coronary sinus ablation (Control group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Additional LA septal line ablation
Number of subjects: 34
Study: 18218295

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17050889

Group type: COMPARATOR
Intervention: DHEA (men)
Number of subjects: 144

Group type: COMPARATOR
Intervention: DHEA (women)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Testosterone (men)
Number of subjects: 144
Study: 14610119

Group type: EXPERIMENTAL
Intervention: Dementia with Lewy bodies (DLB)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 78
Study: 10933118

Group type: EXPERIMENTAL
Intervention: Risperidone for 12 months
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Risperidone for 6 months
Number of subjects: 11
Study: 8874911

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.07 mg/kg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 103
Study: 7980751

Group type: EXPERIMENTAL
Intervention: Rheumatology Nurse Practitioner (RNP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Consultant Rheumatologist (CR)
Number of subjects: 70
Study: 3246212

Group type: EXPERIMENTAL
Intervention: 100 mg trimethoprim (TMP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 500 mg cinoxacin (CNO)
Number of subjects: 26
Study: 30900815

Group type: EXPERIMENTAL
Intervention: 1.8 g/d DHA+EPA
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 3.6 g/d EPA+DHA
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 4.2 g/d ALA
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 7.2 g/d ALA
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 123
Study: 28511172

Group type: EXPERIMENTAL
Intervention: r‐ATG/EVR (n = 85)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: BAS/EVR (n = 102)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: BAS/MPS (n = 101)
Number of subjects: 288
Study: 29871266

Group type: EXPERIMENTAL
Intervention: SLIT + drug group (sublingual immunotherapy with Dermatophagoides farinae drops and symptomatic therapy)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Drug group (mometasone furoate nasal spray and desloratadine tablets)
Number of subjects: 102
Study: 23598691

Group type: EXPERIMENTAL
Intervention: Zinc (50 mg per day for 4 months)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 21854273

Group type: EXPERIMENTAL
Intervention: Buprenorphine tapering schedule
Number of subjects: 892
Study: 18955082

Group type: EXPERIMENTAL
Intervention: Endurance-trained athletes (END)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Power-trained athletes (POW)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 15
Study: 18046666

Group type: EXPERIMENTAL
Intervention: Combined therapy with ACEIs and ARBs
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Monotherapy with ACEIs or ARBs
Number of subjects: 2100
Study: 14730412

Group type: EXPERIMENTAL
Intervention: 60 mg deramciclane
Number of subjects: 15

Group type: COMPARATOR
Intervention: 20 mg paroxetine
Number of subjects: 15
Study: 11563590

Group type: EXPERIMENTAL
Intervention: Medical treatment and secondary prophylaxis during PBSCT
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (patients without IA history)
Number of subjects: 9
Study: 8774617

Group type: EXPERIMENTAL
Intervention: BC-PC (buffy coat platelet concentrates)
Number of subjects: 36

Group type: COMPARATOR
Intervention: SD-PC (single donor platelet concentrates)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fresh PC (day 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Stored PC (day 2-3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Long-stored PC (day 4-5)
Number of subjects: 36
Study: 1338525

Group type: EXPERIMENTAL
Intervention: Captopril (4 mg/l mixed into the cardioplegic solution)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 6143538

Group type: EXPERIMENTAL
Intervention: Betaxolol 5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31122493

Group type: EXPERIMENTAL
Intervention: Co-careldopa (125 mg after initial doses of 62.5 mg)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Co-careldopa
Number of subjects: 593
Study: 30574253

Group type: EXPERIMENTAL
Intervention: Unimproved water sources
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Lack of hand washing at critical times
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Deepening method to take water from a water storage container
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Presence of two or more young siblings
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Rural residence
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Not using latrine for disposal of child feces
Number of subjects: 469
Study: 24344160

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 2865

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 2865

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2865
Study: 24990015

Group type: EXPERIMENTAL
Intervention: Working Memory (WM) Training Program
Number of subjects: 14

Group type: COMPARATOR
Intervention: Poetry‐based Stimulation Program
Number of subjects: 14
Study: 22019079

Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over left DLPFC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over right DLPFC
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study: 20003341

Group type: EXPERIMENTAL
Intervention: Primary care management with the addition of TENS
Number of subjects: 240

Group type: COMPARATOR
Intervention: Primary care management (standard GP consultation, medication, advice and education)
Number of subjects: 240
Study: 17567350

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube S
Number of subjects: 160

Group type: COMPARATOR
Intervention: LMA‐ProSeal
Number of subjects: 160
Study: 15451351

Group type: EXPERIMENTAL
Intervention: Ultrasonographic measurements of the median nerve (cross-sectional area and flattening ratio)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (asymptomatic individuals)
Number of subjects: 131
Study: 11472461

Group type: COMPARATOR
Intervention: Captopril (angiotensin converting enzyme inhibitor)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Atenolol (beta blocker)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 758
Study: 9735735

Group type: EXPERIMENTAL
Intervention: Warm-Up Active Wound Therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 13
Study: 9270567

Group type: EXPERIMENTAL
Intervention: Ropinirole (n = 116) starting dose of 0.25 mg tid, titrated to at least 1.5 mg tid (maximum dose, 8 mg tid)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo (n = 125)
Number of subjects: 241
Study: 2930837

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) or 4‐(9‐acridinylamino)methanesulfan‐m‐anisidide (AMSA) in combination with arabinosylcytosine (Ara‐C) and 6‐thioguanine (TG)
Number of subjects: 57
Study: 861135

Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin tablets (Lanoxin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.2 mg digoxin in solution in soft gelatin capsules (Lanoxicaps)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lanoxicaps (0.2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lanoxin (0.25 mg)
Number of subjects: 10
Study: 28448688

Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 25872532

Group type: EXPERIMENTAL
Intervention: Levothyroxine (25 mcg once daily, increased as needed to maintain TSH between 0.4 to 2.5 mU/L)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23868627

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing Omega‐3, Policosanol, Resveratrol, L‐carnitine, Monascus purpureus, Coenzyme Q10, Vitamin B6 and Vitamin B12
Number of subjects: 80

Group type: COMPARATOR
Intervention: Balanced diet and physical exercise (Control Group B)
Number of subjects: 80
Study: 21944515

Group type: EXPERIMENTAL
Intervention: Regression present
Number of subjects: 2220

Group type: COMPARATOR
Intervention: Regression absent
Number of subjects: 2220
Study: 19786418

Group type: EXPERIMENTAL
Intervention: Nordic Walking training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation programme)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Walking training group
Number of subjects: 80
Study: 16679274

Group type: EXPERIMENTAL
Intervention: SIRRIM technique
Number of subjects: 24
Study: 15575341

Group type: EXPERIMENTAL
Intervention: High-fat meal with dual-wave insulin bolus delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat meal with normal insulin bolus delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control meal with normal insulin bolus delivery
Number of subjects: 0
Study: 11508020

Group type: EXPERIMENTAL
Intervention: Supplementary Family Service Center project
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regular Head Start
Number of subjects: 80
Study: 9422856

Group type: EXPERIMENTAL
Intervention: Anistreplase treatment
Number of subjects: 311

Group type: COMPARATOR
Intervention: TPA versus streptokinase
Number of subjects: 311
Study: 8236505

Group type: EXPERIMENTAL
Intervention: IL-2 plus L-carnitine (1000 mg/day orally)
Number of subjects: 30

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 30
Study: 3683810

Group type: EXPERIMENTAL
Intervention: Horizontal word orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vertical word orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imageability with horizontal displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imageability effects between visual fields
Number of subjects: 0
Study: 29326124

Group type: COMPARATOR
Intervention: Conventional tacrolimus/methotrexate (A)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Bortezomib/tacrolimus/methotrexate (B)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Bortezomib/sirolimus/tacrolimus (C)
Number of subjects: 138
Study: 28403865

Group type: EXPERIMENTAL
Intervention: 360° Quantified Self (360QS) methodology using wearable sensors, mobile and social media for data collection.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 360° Quantified Self (360QS) methodology
Number of subjects: 50
Study: 26090707

Group type: EXPERIMENTAL
Intervention: Kinesio Tape (KT) application
Number of subjects: 27

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 27
Study: 22464647

Group type: EXPERIMENTAL
Intervention: ILIT with MAT-Fel d 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline in alum)
Number of subjects: 0
Study: 20461089

Group type: EXPERIMENTAL
Intervention: GP-led melanoma follow-up
Number of subjects: 142